2022-501361-44-00撤回3 期
A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimilar (DRL_Tocilizumab) with tocilizumab reference product (RoActemra®) administered by the subcutaneous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 入组人数
- 357
- 试验地点
- 47
- 主要终点
- The following parameters will be compared between patients treated with DRL_TC and RMP: Primary endpoint for EMA: • Change in DAS28-ESR from Baseline to Week 13 [Time Frame: Baseline; Week 13]
研究概览
简要总结
To compare efficacy measured as change from baseline to Week 13 in DAS28-ESR following treatment with DRL_TC or RMP in a population of patients with moderate to severe rheumatoid arthritis on treatment with MTX.
研究设计
- 分配方式
- Randomized
- 主要目的
- Long-term Extension Phase
- 盲法
- Double (Monitor, Investigator, Analyst, Subject)
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Male or female patient aged ≥ 18 years and ≤ 80 years and willing to voluntarily provide informed consent for participation as per the locally applicable regulations.
- •Patient must be able to self-administer or must have help to administer the study treatment by caregiver.
- •Patient must be able to comply with all study requirements in the opinion of the Investigator.
- •Patient with active moderate to severe rheumatoid arthritis of at least 6 months duration, as per ACR 1987 revised criteria for the classification of Rheumatoid Arthritis.
- •Patients with: a. Swollen Joint Count (SJC) ≥ 6 b. Tender Joint Count (TJC) ≥ 8 c. Erythrocyte Sedimentation Rate (ESR) ≥ 28 mm/ hour
- •Patient must have been treated with stable doses of MTX (at least 15 mg/ week, not exceeding allowed maximum dose in the country-specific label; at least 6 mg/ week for patients from other Eastern Asia countries) for at least 8 weeks prior to randomisation. a. Patients who cannot tolerate higher dose of MTX should be on stable dose of tolerable dose of MTX for 8 weeks prior to study entry (there should be documented evidence of intolerance to MTX).
- •Patient taking MTX must be on a stable dose of folic acid (≥ 5 mg per week) or equivalent. Patient must have received folic acid or equivalent for at least 2 months and at a stable dose for 4 weeks prior to randomisation.
- •If the patient is on any of these cDMARDs or bDMARDs, an adequate washout period needs to be completed before first dose of study drug: hydroxychloroquine, chloroquine, azathioprine, leflunomide, sulfasalazine, cyclophosphamide, TNF inhibitors, abatacept, rituximab. Refer Section 10.3 for further details on washout periods.
- •Patient on glucocorticoids should not be receiving more than 10 mg oral prednisone/ prednisolone or equivalent per day, and those receiving should be using stable dose for at least 6 weeks prior to randomisation.
- •For patient receiving NSAIDs, a stable dose not higher than the maximum recommended dose for the agent in the Prescribing Information of the country where the centre is located for the last 4 weeks prior to randomisation.
- •Woman of childbearing potential should have a negative pregnancy test and should agree to use reliable means of contraception and not to donate or cryopreserve ova during the course of the study and for at least 6 months after the last dose of the study drug. OR Male patient permanently sterile by bilateral orchidectomy or agree to use appropriate contraception methods (see list in the Note below) and not to donate or cryopreserve sperm during the study and for at least 6 months after the last dose of study drug.
排除标准
- •Patients who have received prior treatment with tocilizumab (even if tocilizumab was used for COVID-19 treatment, patient should be excluded), or other agents directly acting on the IL-6 signalling axis (e.g. sirukumab, olokizumab etc.).
- •Patients with active tuberculosis, unrecovered hepatitis B, herpes zoster including the period of post-herpetic neuralgia within 1 year of randomisation, or any other ongoing clinically relevant active infection, even if localised.
- •Patients with any history or current presence of known demyelinating disease.
- •Patients with any history of or presence of an active neoplasia except for successfully treated (at least five years in advance) non-metastatic cutaneous squamous cell or basal cell carcinoma and ⁄or localised carcinoma in situ of the cervix.
- •Patients with renal impairment (Cockcroft-Gault creatinine clearance < 60 ml/ min) or liver function impairment (bilirubin > 1.25 x ULN, albumin < 3.5 g/ dL, INR > 1.25, ALT or AST > 1.5 x ULN) at screening.
- •Patients with any disorder or treatment that, in the Investigator’s opinion, may interfere with the safety of the patient, the study evaluations, or the patient compliance to the study procedures and limitations, such as history of chronic alcohol or drug abuse, or significant (for the purposes of the study in the opinion of the Investigator) endocrinological, cardiac, respiratory, mental, or nervous disorder or other diseases. Special focus should be given to lung conditions to ensure it is sufficiently close to normal to avert excessive risks upon study participation.
- •Patients with absolute neutrophil count (ANC) < 2 x 109/ L or platelet count < 100 x 109/ L at the time of screening.
- •Patients with clinically relevant hyperlipidaemia (fasting serum LDL cholesterol higher than 190 mg/ dL or fasting serum triglycerides higher than 200 mg/ dL despite treatment with antihyperlipidemic drugs) at the time of screening. Note: Repeat tests up to two times are allowed as per Investigator’s discretion.
- •Patients who have received treatment with IV gamma globulin or plasmapheresis within 6 months of randomisation.
- •Patients with known contraindication to treatment with tocilizumab, including, but not restricted to hypersensitivity to tocilizumab, other monoclonal antibodies, or any excipients (L-arginine hydrochloride, L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 80).
- •Patients who received live virus vaccination within 3 months prior to randomization or intention to receive live virus vaccination during the trial or up to 3 months after the end of administration of the study drug.
- •Patients who need concomitant rheumatoid arthritis therapies other than a. methotrexate with folic acid (at a dose of at least 5 mg per week [or equivalent]) (methotrexate and folic acid will be kept at a stable dose during the study); b. nonsteroidal anti-inflammatory drugs at approved doses kept at stable doses during the study; c. corticosteroids at a maximum daily dose of 10 mg of oral prednisone or equivalent; or d. an analgesics-free period of appropriate duration (12 hr for analgesics in general; 24 hr for oxicams and other single daily or less frequently administered drugs) cannot be maintained before patient evaluation visit. Note: Aspirin at anti-aggregant doses (up to 325 mg per day) is not considered an analgesic.
- •Patients with positive screening for hepatitis B, hepatitis C or HIV.
- •Patients with active diverticulitis or other GI condition having high risk of perforation as per investigator’s judgement.
- •Patients with unhealed clinically significant external wounds.
- •Female patients who are currently pregnant or breastfeeding.
- •Patients with known history of or current abuse of alcohol or illegal drugs (testing not required).
- •Patients who are considered unreliable to follow study requirements and restrictions, in the opinion of the Investigator.
- •Patients who had major surgery including joint surgery within 8 weeks prior to randomisation or planned major surgery within 6 months following randomisation.
- •Patients who have received any treatment with intra-articular injections (e.g., corticosteroids) required for a flare-up and up to 4 weeks prior to randomization.
- •Patients with functional class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis.
- •Patients with other inflammatory diseases that might confound the evaluation of the efficacy (e.g., Crohn’s disease, ulcerative colitis). Note: Sjogren syndrome secondary to rheumatoid arthritis is allowed.
- •Patients who have received any investigational drug within 30 days or 5 times half-life, whichever is longer, prior to the first dose of study drug (or longer as per the local regulation of the country). Patients participating/ participated in another clinical trial evaluating a bDMARD for RA in the last year before Screening are not eligible for this trial.
- •Patients with a known history of or presence of clinically significant haematological, cardiovascular (any patient with NYHA III/ IV functional status is to be excluded), renal, or liver disease.
- •Patients with diseases that have immune suppression in their clinical course and/ or need for treatment with immune suppressive treatments such as patients with an organ graft requiring maintenance immune suppression.
- •Patients with latent tuberculosis including patients with positive and indeterminate QuantiFERON-TB test at screening (QuantiFERON-Gold TB or other validated tuberculosis screening Interferon Gamma Release Assay). Note: For indeterminate results, two repeats are allowed. In emergent situations, when the patient needs quick therapy for RA, patient may be re-tested and randomised after completing at least 4 weeks of prophylactic treatment. As a standard approach, optimal prophylactic therapy should last 3 months with relevant medications and treatment confirmed as effective in patient documentation before randomization.
结局指标
主要结局
The following parameters will be compared between patients treated with DRL_TC and RMP: Primary endpoint for EMA: • Change in DAS28-ESR from Baseline to Week 13 [Time Frame: Baseline; Week 13]
The following parameters will be compared between patients treated with DRL_TC and RMP: Primary endpoint for EMA: • Change in DAS28-ESR from Baseline to Week 13 [Time Frame: Baseline; Week 13]
次要结局
- • Change from Baseline in DAS28-CRP [Time Frame: Baseline; Week 5; Week 9; Week 13; Week 17; Week 21; and Week 25] • Proportion of patients with ACR20/ 50/ 70 response [Time Frame: Week 5; Week 9; Week 13; Week 17; Week 21; and Week 25]
- The following parameters will be compared between patients treated with DRL_TC and RMP:Efficacy: • Change from Baseline in DAS28-ESR [Time Frame: Baseline; Week 5; Week 9; Week 13 (for US FDA); Week 17; Week 21; and Week 25 (for EMA)]
- • Time to EULAR moderate or good response [Time Frame: Week 5; Week 9; Week 13; Week 17; Week 21; and Week 25] • Proportion of patients reaching moderate or good EULAR response based on DAS28-ESR [Time Frame: Week 5; Week 9; Week 13; Week 17; Week 21; and Week 25]
- Safety: • Incidence of AEs and SAEs [Time Frame: Baseline till EOS; different study periods will be separately considered] • Incidence of AEs and SAEs during transition phase [Time Frame: Week 25; Week 33]
- Pharmacodynamics: • Change in PD endpoints from baseline to selected time points [Time Frame: Baseline through scheduled time points]
- • Incidences of anaphylactic reactions, hypersensitivity reactions, and injection site reactions [Time Frame: Baseline till EOS; different study periods will be separately considered] • Incidence of anaphylactic reactions, hypersensitivity reactions, and injection site reactions during transition phase [Time Frame: Week 25; Week 33]
- Immunogenicity: • Incidence of ADAs including NAb and ADA Titres [Time Frame: Baseline through scheduled time points till EOS; different study periods will be separately considered] • Incidence of ADAs including NAb and ADA Titres during transition phase [Time Frame: Week 25; Week 33]
- Pharmacokinetics: • Population pharmacokinetic parameters [Time Frame: Baseline through scheduled time points till EOS]
研究者
Dr. Piyushbhai Patel
Scientific
Dr. Reddy's Laboratories Limited
研究点 (47)
Loading locations...
相似试验
招募中
4 期
Efficacy, tolerability and preferences of per oral or subcutaneous methotrexate in patients with early rheumatoid arthritis – a randomised register based multicentre studyRheumatoid arthritis2024-512453-25-00Region Vaesterbotten212
招募中
2 期
Study that aims to investigate how effective and safe the use of a novel modified release tablet formulation of Colesevelam hydrochloride-MMX is for patients with idiopathic bile acid diarrhoea (BAD), randomly allocated to 2 different dose regimens of the active product or to the inactive placebo formulation.2024-511993-55-00Cosmo Technologies Limited120
已完成
4 期
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis2023-504869-23-00AbbVie Deutschland GmbH & Co. KG272
尚未招募
不适用
Mechanisms Underlying SGLT2i Kidney Effect in DKD ProgressionNCT07270198Mario Negri Institute for Pharmacological Research100
招募中
2 期
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCNCT07269782Shanghai Henlius Biotech60